This suggests that the decreased CD16+ expression we show, on intermediate and non-classical monocytes, associated with increased asthma severity may be due to the fact that monocytes are recently released from the bone marrow and have not yet acquired full CD16 expression. This evidence concerns the gene FCGR3A and asthma.